Maria Sargent
Family · Grayson, KYNPI 1023191392
Payments from drug & device makers
Across 413 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AbbVie$1K
- Novo Nordisk$757
- Lilly USA, LLC$518
- AstraZeneca$490
- Supernus Pharmaceuticals, Inc.$457
- plus $2K from 30 others
What the payments were for
- Food & beverage$6,724100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 86 | $1,227 |
| AbbVie | 63 | $1,075 |
| Novo Nordisk | 54 | $757 |
| Lilly USA, LLC | 36 | $518 |
| AstraZeneca | 21 | $490 |
| Supernus Pharmaceuticals, Inc. | 9 | $457 |
| Boehringer Ingelheim | 17 | $234 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $207 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $172 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $168 |
| Merck | 10 | $141 |
| Kowa Pharmaceuticals America, Inc. | 11 | $126 |
| Exact Sciences | 7 | $115 |
| Novartis | 7 | $103 |
| Pfizer | 6 | $92 |
| Biohaven Pharmaceuticals, Inc. | 5 | $90 |
| Phathom Pharmaceuticals, Inc. | 5 | $90 |
| Dexcom, Inc. | 6 | $83 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $81 |
| Corcept Therapeutics | 4 | $70 |
| Sanofi-aventis U.S. LLC | 4 | $51 |
| Johnson & Johnson | 3 | $43 |
| Esperion Therapeutics, Inc. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Amgen | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Genentech USA, Inc. | 3 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $19 |
| Evoke Pharma, Inc. | 1 | $19 |
| Bausch Health US, LLC | 1 | $18 |
| Abbott | 1 | $17 |
| Sobi, Inc | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Heartflow, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$372
How this compares
$6,724 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 23 | $31,459 |
| MounjaroTirzepatide | 26 | $28,368 |
| EliquisApixaban | 18 | $26,479 |
| OzempicSemaglutide | 18 | $22,380 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $19,889 |
| JanuviaSitagliptin Phosphate | 24 | $18,806 |
| TradjentaLinagliptin | 20 | $15,682 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $8,489 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $6,936 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $5,752 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $2,941 |
| Potassium Chloride | 69 | $2,182 |
| Rosuvastatin Calcium | 159 | $2,020 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 24 | $1,780 |
| Levocetirizine Dihydrochloride | 92 | $1,496 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $234 | $47,14243 claims |
| Lilly USA, LLCMounjaro | $518 | $28,36826 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,227 | $26,82528 claims |
| PfizerEliquis | $92 | $26,47918 claims |
| Novo NordiskOzempic | $757 | $22,38018 claims |
| MerckJanuvia | $141 | $18,80624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.
Other family in Grayson
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.